这是一项开放标签、随机、2臂、多中心、第三期研究，主要目标是比较brentuximab vedotin（ADCETRIS®）加上AVD（doxorubicin［Adriamycin］、vinblastine及dacarbazine；简称A+AVD）与ABVD（doxorubicin［Adriamycin］、bleomycin、vinblastine及dacarbazine）用于晚期典型何杰金氏淋巴瘤（HL）第一线治疗所达到的修订版无进展生存期（mPFS）。
适应症：Hodgkin Lymphoma
入组条件
纳入标准
- Treatment-naïve participants with Ann Arbor Stage III or IV HL.
- Histologically confirmed classical Hodgkin Lymphoma (HL) according to the current World Health Organization (WHO) classification.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\<=) 2.
- Bidimensional measurable disease as documented by radiographic technique per the International Working Group Revised Criteria for Response Assessment for Malignant Lymphoma.
排除标准
- Nodular lymphocyte predominant Hodgkin lymphoma.
- Cerebral/meningeal disease, including signs and symptoms of progressive multifocalleukoencephalopathy (PML).
- Sensory or motor peripheral neuropathy.
- Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 12 weeks of first study drug dose.
- Known human immunodeficiency virus (HIV) positive.
- Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。